Vicapsys Life Sciences Stock Performance
| VICP Stock | USD 7.00 0.00 0.00% |
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Vicapsys Life are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Vicapsys Life Sciences has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable fundamental indicators, Vicapsys Life is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 264.2 K | |
| Total Cashflows From Investing Activities | 100 K | |
| Free Cash Flow | -262.9 K |
Vicapsys |
Vicapsys Life Relative Risk vs. Return Landscape
If you would invest 700.00 in Vicapsys Life Sciences on September 19, 2024 and sell it today you would earn a total of 0.00 from holding Vicapsys Life Sciences or generate 0.0% return on investment over 90 days. Vicapsys Life Sciences is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Vicapsys, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vicapsys Life Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vicapsys Life's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Vicapsys Life Sciences, and traders can use it to determine the average amount a Vicapsys Life's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| VICP |
Based on monthly moving average Vicapsys Life is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vicapsys Life by adding Vicapsys Life to a well-diversified portfolio.
Vicapsys Life Fundamentals Growth
Vicapsys Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Vicapsys Life, and Vicapsys Life fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vicapsys Pink Sheet performance.
| Return On Equity | -10.59 | |||
| Return On Asset | -0.8 | |||
| Current Valuation | 31.17 M | |||
| Shares Outstanding | 31.19 M | |||
| Price To Book | 0.02 X | |||
| Price To Sales | 0 X | |||
| EBITDA | (734.42 K) | |||
| Cash And Equivalents | 17.29 K | |||
| Debt To Equity | 285.70 % | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (262.9 K) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 404.12 K | |||
About Vicapsys Life Performance
Assessing Vicapsys Life's fundamental ratios provides investors with valuable insights into Vicapsys Life's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Vicapsys Life is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN proprietary product. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia. Vicapsys Life operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.Things to note about Vicapsys Life Sciences performance evaluation
Checking the ongoing alerts about Vicapsys Life for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Vicapsys Life Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vicapsys Life generated a negative expected return over the last 90 days | |
| Vicapsys Life has a very high chance of going through financial distress in the upcoming years | |
| Vicapsys Life has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Vicapsys Life until it has trouble settling it off, either with new capital or with free cash flow. So, Vicapsys Life's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vicapsys Life Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vicapsys to invest in growth at high rates of return. When we think about Vicapsys Life's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (765.84 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Vicapsys Life Sciences currently holds about 17.29 K in cash with (262.9 K) of positive cash flow from operations. | |
| Roughly 46.0% of the company outstanding shares are owned by insiders |
- Analyzing Vicapsys Life's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vicapsys Life's stock is overvalued or undervalued compared to its peers.
- Examining Vicapsys Life's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vicapsys Life's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vicapsys Life's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vicapsys Life's pink sheet. These opinions can provide insight into Vicapsys Life's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Vicapsys Pink Sheet Analysis
When running Vicapsys Life's price analysis, check to measure Vicapsys Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vicapsys Life is operating at the current time. Most of Vicapsys Life's value examination focuses on studying past and present price action to predict the probability of Vicapsys Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vicapsys Life's price. Additionally, you may evaluate how the addition of Vicapsys Life to your portfolios can decrease your overall portfolio volatility.